Paper40064751
Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models.
Partyka A and 13 others. Pharmacol Rep, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models. Papers, record 40064751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40064751
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antidepressive Agents | Major topic |
| Anti-Anxiety Agents | Major topic |
| Quinolones | Major topic |
| Thiophenes | Major topic |
| Sulfonamides | Major topic |
| Isoquinolines | Major topic |
| Nootropic Agents | Major topic |
| Animals | |
| Male | |
| Rats | |
| Mice | |
| Antipsychotic Agents | |
| Disease Models, Animal | |
| Cognition | |
| Humans | |
| Behavior, Animal |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| UGA POIG.01.03.01-12-063/09-00 | project Prokog, European Fund of Regional Development (EFRD) | PubMed |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 40445584 | Correction: Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models. | https://conductscience.org/library/papers/40445584 |
Source PubMed
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23810019 | Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. | Lancet | 2013 | https://conductscience.org/library/papers/23810019 | PubMed |
| 2 | 29407591 | Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects. | Eur J Med Chem | 2018 | https://conductscience.org/library/papers/29407591 | PubMed |
| 3 | 21394633 | Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. | Psychopharmacology (Berl) | 2011 | https://conductscience.org/library/papers/21394633 | PubMed |
| 4 | 25448429 | Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats. | Behav Brain Res | 2015 | https://conductscience.org/library/papers/25448429 | PubMed |
| 5 | 37386328 | The Serotonin 1A (5-HT1A) Receptor as a Pharmacological Target in Depression. | CNS Drugs | 2023 | https://conductscience.org/library/papers/37386328 | PubMed |
| 6 | 23757185 | Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. | CNS Drugs | 2013 | https://conductscience.org/library/papers/23757185 | PubMed |
| 7 | 24501158 | The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia. | Rev Neurosci | 2014 | https://conductscience.org/library/papers/24501158 | PubMed |
| 8 | 21115035 | The treatment of cognitive impairment in schizophrenia. | Pharmacol Biochem Behav | 2011 | https://conductscience.org/library/papers/21115035 | PubMed |
| 9 | 19337725 | Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. | Psychopharmacology (Berl) | 2009 | https://conductscience.org/library/papers/19337725 | PubMed |
| 10 | 18948124 | 5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT1A receptor. | Neuropharmacology | 2009 | https://conductscience.org/library/papers/18948124 | PubMed |
| 11 | 22659581 | Microinjection of the 5-HT7 receptor antagonist SB-269970 into the rat brainstem and basal forebrain: site-dependent effects on REM sleep. | Pharmacol Biochem Behav | 2012 | https://conductscience.org/library/papers/22659581 | PubMed |
| 12 | 16613552 | The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. | CNS Neurol Disord Drug Targets | 2006 | https://conductscience.org/library/papers/16613552 | PubMed |
| 13 | 24488407 | α2-Adrenoceptors are targets for antipsychotic drugs. | Psychopharmacology (Berl) | 2014 | https://conductscience.org/library/papers/24488407 | PubMed |
| 14 | 26899451 | Mechanism of action of brexpiprazole: comparison with aripiprazole. | CNS Spectr | 2016 | https://conductscience.org/library/papers/26899451 | PubMed |
| 15 | 23279866 | Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors. | Eur J Med Chem | 2013 | https://conductscience.org/library/papers/23279866 | PubMed |
| 16 | 27326337 | N1-Azinylsulfonyl-1H-indoles: 5-HT6 Receptor Antagonists with Procognitive and Antidepressant-Like Properties. | ACS Med Chem Lett | 2016 | https://conductscience.org/library/papers/27326337 | PubMed |
| 17 | 30188719 | Amino Acid Hot Spots of Halogen Bonding: A Combined Theoretical and Experimental Case Study of the 5-HT7 Receptor. | J Med Chem | 2018 | https://conductscience.org/library/papers/30188719 | PubMed |
| 18 | 28529043 | The impact of the halogen bonding on D2 and 5-HT1A/5-HT7 receptor activity of azinesulfonamides of 4-[(2-ethyl)piperidinyl-1-yl]phenylpiperazines with antipsychotic and antidepressant properties. | Bioorg Med Chem | 2017 | https://conductscience.org/library/papers/28529043 | PubMed |
| 19 | 25131522 | Novel tricyclic[2,1-f]theophylline derivatives of LCAP with activity in mouse models of affective disorders. | J Pharm Pharmacol | 2014 | https://conductscience.org/library/papers/25131522 | PubMed |
| 20 | 34467765 | Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT3 and 5-HT6 Receptor Antagonist with Antipsychotic and Procognitive Properties. | J Med Chem | 2021 | https://conductscience.org/library/papers/34467765 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| HTR1A | 3350 | PubTator's text mining | https://conductscience.org/library/genes/3350 | NCBI Gene |
| HTR2A | 3356 | PubTator's text mining | https://conductscience.org/library/genes/3356 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40064751
GET https://conductscience.org/api/papers/v1/40064751/references?page=2